Search

Madrigal Pharmaceuticals Inc

Fermé

SecteurSoins de santé

531.75 -0.16

Résumé

Variation du prix de l'action

24h

Actuel

Min

529.14

Max

546.26

Chiffres clés

By Trading Economics

Revenu

36M

-58M

Ventes

53M

364M

BPA

-1.99

Marge bénéficiaire

-15.906

Employés

915

EBITDA

30M

-56M

Dividendes

By Acuity

Prochains Résultats

3 nov. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-208M

13B

Ouverture précédente

531.91

Clôture précédente

531.75

Sentiment de l'Actualité

By Acuity

26%

74%

55 / 339 Classement par Healthcare

Madrigal Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

10 sept. 2026, 20:03 UTC

Social Media

Madrigal Pharmaceuticals shares are lower as CEO highlights MASH sector potential at the Cantor Fitzgerald conference amid broader market volatility and ECB rate hike effects.

3 sept. 2026, 19:36 UTC

Social Media

Madrigal Pharmaceuticals is presenting five abstracts on MASH at the Paris conference on September 10, as shares trade lower today.

2 sept. 2026, 21:01 UTC

Madrigal Pharmaceuticals is trading lower in after-market hours amid broader market weakness and unusual inactivity, though it remains above its 20-day moving average.

1 sept. 2026, 19:36 UTC

Madrigal Pharmaceuticals shares are declining amid rising oil prices and inflation concerns. The stock initially reached a session high earlier in the session.

31 août 2026, 21:01 UTC

Madrigal Pharmaceuticals shares are lower in after-market trading, fluctuating within a narrow range amid broader market sentiment influenced by Fed Chair Kevin Warsh's remarks.

28 août 2026, 19:56 UTC

Madrigal Pharmaceuticals Inc shares are lower today, with no specific news identified. Broader market sentiment may be affected by inflation concerns from a Federal Reserve official.

27 août 2026, 21:01 UTC

Madrigal Pharmaceuticals Inc shares are higher in after-market trading, continuing a cumulative gain since Thursday's close, with no specific news identified.

26 août 2026, 22:01 UTC

Madrigal Pharmaceuticals shares are higher in after-market trading, reaching a peak of 1.05% above Wednesday's close, with no specific news identified.

21 août 2026, 19:46 UTC

Madrigal Pharmaceuticals is lower in Friday's session, retracing from an earlier peak amid broader market pressures from rising Treasury yields and inflation concerns.

20 août 2026, 23:46 UTC

Madrigal Pharmaceuticals shares are lower in after-market trading. Broader market declines are attributed to rising crude oil prices and geopolitical tensions.

18 août 2026, 19:56 UTC

Madrigal Pharmaceuticals shares are lower today amid rising Treasury yields, which may be influencing investor sentiment. Earlier, the stock pulled back from a session high.

17 août 2026, 19:35 UTC

Madrigal Pharmaceuticals is trading higher today, continuing gains since Friday's close, despite no specific company news driving the upward movement.

14 août 2026, 19:26 UTC

Social Media

Madrigal Pharmaceuticals launches a Phase 2a study for resmetirom. Shares are lower today, pulled back from earlier gains amid broader market concerns over retail sales.

13 août 2026, 21:01 UTC

Madrigal Pharmaceuticals Inc shares are higher in after-market trading, showing notable movement since Thursday's close, though no specific news explains the price action.

12 août 2026, 21:01 UTC

Madrigal Pharmaceuticals shares are higher in after-market trading. Positive market sentiment follows comments on CPI reports that may impact Federal Reserve interest rate decisions.

10 août 2026, 19:16 UTC

Madrigal Pharmaceuticals Inc shares are higher, despite no specific news. Broader market conditions reflect a decline in U.S. stock futures amid job data.

7 août 2026, 20:02 UTC

Madrigal Pharmaceuticals shares are lower during Friday's session, continuing a decline since Thursday. The stock remains below its 20-day moving average.

6 août 2026, 21:01 UTC

News

Madrigal Pharmaceuticals granted equity inducement awards to ten new employees, boosting shares modestly higher in after-market trading.

4 août 2026, 20:04 UTC

Social Media
News

Madrigal Pharmaceuticals upgraded to Outperform by Wolfe Research, with a price target of $605. Shares are higher since Monday, despite a pullback earlier today.

3 août 2026, 19:31 UTC

News
Social Media

Madrigal Pharmaceuticals shares are higher as CEO Bill Sibold notes market hesitance toward IVA due to weight gain concerns. The broader market also advances.

31 juil. 2026, 23:06 UTC

Madrigal Pharmaceuticals Inc shares are lower in after-market hours with no specific news identified. The stock remains near the lower end of its one-month range.

30 juil. 2026, 19:27 UTC

News

Madrigal Pharmaceuticals shares are lower following a widened second-quarter net loss of $57.9 million and increased operating expenses of $420.6 million.

29 juil. 2026, 22:26 UTC

Madrigal Pharmaceuticals shares are lower in after-market hours, reflecting broader market volatility following the Federal Reserve's interest rate decision and inflation concerns.

28 juil. 2026, 18:46 UTC

Madrigal Pharmaceuticals is lower today, continuing a broader decline since Monday's close. No specific news has been identified to explain the movement.

27 juil. 2026, 23:56 UTC

Madrigal Pharmaceuticals Inc is trading higher in after-market hours, reflecting a notable increase since Monday's close, despite no specific news identified.

20 juil. 2026, 16:02 UTC

Social Media

Madrigal Pharmaceuticals is lower today amid aggressive call buying and heightened market volume, with broader inflation concerns influenced by geopolitical tensions.

Comparaison

Variation de prix

Madrigal Pharmaceuticals Inc prévision

Note du Consensus

By TipRanks

Achat Fort

13 ratings

12

Achat

1

Maintien

0

Vente

Sentiment

By Acuity

55 / 339Classement par Soins de santé

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
help-icon Live chat